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The homozygous appearance of the intronic mutation (IVS6-1) in the MYL2 gene
encoding for myosin ventricular/slow-twitch skeletal regulatory light chain (RLC) was
recently linked to the development of slow skeletal muscle fiber type I hypotrophy and
early cardiac death. The IVS6-1 (c403-1G>C) mutation resulted from a cryptic splice site
inMYL2 causing a frameshift and replacement of the last 32 codons by 19 different amino
acids in the RLC mutant protein. Infants who were IVS6-1+/+-positive died between 4
and 6 months of age due to cardiomyopathy and heart failure. In this report we have
investigated the molecular mechanism and functional consequences associated with
the IVS6-1 mutation using recombinant human cardiac IVS6-1 and wild-type (WT) RLC
proteins. Recombinant proteins were reconstituted into RLC-depleted porcine cardiac
muscle preparations and subjected to enzymatic and functional assays. IVS6-1-RLC
showed decreased binding to the myosin heavy chain (MHC) compared with WT, and
IVS6-1-reconstituted myosin displayed reduced binding to actin in rigor. The IVS6-1
myosin demonstrated a significantly lower Vmax of the actin-activated myosin ATPase
activity compared with WT. In stopped-flow experiments, IVS6-1 myosin showed slower
kinetics of the ATP induced dissociation of the acto-myosin complex and a significantly
reduced slope of the kobs-[MgATP] relationship compared to WT. In skinned porcine
cardiac muscles, RLC-depleted and IVS6-1 reconstituted muscle strips displayed a
significant decrease in maximal contractile force and a significantly increased Ca2+
sensitivity, both hallmarks of hypertrophic cardiomyopathy-associated mutations in
MYL2. Our results showed that the amino-acid changes in IVS6-1 were sufficient to
impose significant conformational alterations in the RLC protein and trigger a series
of abnormal protein-protein interactions in the cardiac muscle sarcomere. Notably, the
mutation disrupted the RLC-MHC interaction and the steady-state and kinetics of the
acto-myosin interaction. Specifically, slower myosin cross-bridge turnover rates and
slower second-order MgATP binding rates of acto-myosin interactions were observed
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in IVS6-1 vs. WT reconstituted cardiac preparations. Our in vitro results suggest that
when placed in vivo, IVS6-1 may lead to cardiomyopathy and early death of homozygous
infants by severely compromising the ability of myosin to develop contractile force and
maintain normal systolic and diastolic cardiac function.
Keywords: cardioskeletal myopathy, actin-myosin interaction, fluorescence measurements, myosin ATPase,
muscle contraction
INTRODUCTION
A new skeletal muscle fiber type-I myopathy with progressive
cardiomyopathy and the early death of infants due to cardiac
failure was reported in three unrelated Dutch families by Barth
et al. (1998). It was not until recently that the genetic cause
of this cardioskeletal disorder was identified by Weterman
et al. (2013), and related to mutations in the MYL2 gene
encoding for the ventricular and slow-twitch skeletal myosin
regulatory light chain (RLC). To date, about 16 single amino
acid mutations in MYL2 have been linked to various forms
of cardiomyopathy (Poetter et al., 1996; Flavigny et al., 1998;
Andersen et al., 2001, 2009; Kabaeva et al., 2002; Richard et al.,
2003; Olivotto et al., 2008; Garcia-Pavia et al., 2011; Claes et al.,
2015; Huang et al., 2015). The IVS6-1 (c403-1G>C) mutation,
associated with the slow-skeletal and cardiac muscle myopathy,
resulted from a cryptic splice site upstream of the last exon
of MYL2 causing a frameshift and replacement of the last 32
codons by 19 different codons (Weterman et al., 2013). As a
consequence, the C-tail of the RLC protein was truncated and
contained a completely altered C-terminal amino acid sequence
compared with wild-type (WT) RLC (NCBI accession # P10916)
(Figure 1A). Immunohistochemical staining of skeletal muscle
tissue of the Dutch patients homozygous for IVS6-1 showed
a diffuse and weak expression of the mutant protein without
clear fiber specificity, while the normal RLC protein was absent
(Weterman et al., 2013). Therefore, in this report we aimed
at elucidating the potential molecular mechanism by which
the IVS6-1 mutation may exert its effects on cardiac muscle
contraction. This process is highly dependent upon the integrity
of myosin, including its two heavy chains (MHC) and the
regulatory and essential (ELC) light chains (Holmes and Geeves,
2000), and such drastic amino acid changes in the sequence of
RLC due to IVS6-1 are likely to affect the interaction of myosin
with actin, force production and lead to cardiac dysfunction
responsible for infantile death of IVS6-1 homozygous patients
(Barth et al., 1998; Weterman et al., 2013).
Previous studies from our lab demonstrated that single amino
acid mutations in the RLC protein shown to be associated
with hypertrophic cardiomyopathy (HCM), were able to cause
significant changes in the secondary structure of RLC, as well as
in the Ca2+ binding and phosphorylation properties (Szczesna
et al., 2001). They also adversely affected the function of mutated
Abbreviations: CD, Circular Dichroism; DCM, dilated cardiomyopathy; ELC,
essential light chain of myosin; HCM, hypertrophic cardiomyopathy; IVS6-1,
splice site intronic mutation in MYL2; MHC, myosin heavy chain; MYL2, gene
encoding for human ventricular RLC; RLC, regulatory light chain of myosin; Tm,
tropomyosin; Tn, troponin; WT, wild-type.
myosin and its ability to interact with actin and produce
contractile force (Szczesna-Cordary et al., 2004; Greenberg et al.,
2010; Farman et al., 2014; Muthu et al., 2014; Karabina et al.,
2015). In this report we have examined, for the first time, the
effect of the IVS6-1 mutation on the molecular rearrangements
in the RLC and the function of mutant myosin in vitro. The
interactions of IVS6-1 with the MHC, and the mutant myosin
with actin were investigated using recombinant human cardiac
RLC proteins, IVS6-1 vs. WT, that could be reconstituted into
porcine cardiac muscle preparations, myosin and skinnedmuscle
strips. Prior to reconstitution, the preparations were stripped
of endogenous porcine cardiac RLC. We show that in a way
similar to that of other HCM causing mutations in myosin RLC,
the IVS6-1 mutation induced significant changes in the RLC
structure and the function of mutant myosin compromising its
interaction with actin and ultimately leading to dysregulated
cardiac muscle contraction.
MATERIALS AND METHODS
Cloning, Expression and Purification of
Wild-Type (WT) Human Cardiac RLC and
the IVS6-1 Mutant
The RLC WT was cloned, expressed and purified as previously
described (Szczesna et al., 2001). The cDNA of IVS6-1 was
synthesized and inserted in the pCR2.1 vector by Eurofins MWG
OperonTM. The plasmid was amplified in Subcloning EfficiencyTM
DH5αTM competent cells (Invitrogen) and was transformed
into BL21(DE3) competent cells (Agilent Technologies) for
expression. Similar to WT, the IVS6-1 mutant protein was
purified using an S-Sepharose column followed by a Q-Sepharose
column chromatography (GE Healthcare Life Science). The
S-Sepharose column was equilibrated with 6M urea, 20mM
Citrate, 0.1mM phenylmethylsulfonyl fluoride (PMSF), 1mM
dithiothreitol (DTT), 0.02% NaN3, pH 6.0. Proteins were eluted
using 800ml salt gradient of 0−450mM NaCl. For Q-Sepharose
purification the following buffer was used: 3M urea, 25mM
Tris-HCl, pH 7.5, 0.1mM PMSF, 1mM DTT, and 0.02% NaN3,
and proteins were eluted with a 1000ml salt gradient of
0–450mM KCl. The final purity of the proteins was assessed
by 15% SDS-PAGE. The N-terminal peptide RLC antibody
(NT-1 RLC, anti-rabbit, aa 7–21) and the C-terminal peptide
RLC antibody (CT-1, anti-rabbit, aa 143–156), both produced
in this laboratory (Wang et al., 2006), were used to verify
the quality and purity of IVS6-1 and WT proteins. Proteins
were stored in Q-Sepharose buffer at −80◦C until used in
experiments.
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FIGURE 1 | (A) Amino acid sequences of myosin RLC WT and IVS6-1 mutant protein. IVS6-1 is a splice site mutation 1 (c403-1G>C) that occurs in Intron 6 of the
MYL2 gene encoding for the human ventricular RLC/ slow-twitch skeletal muscle RLC. As a consequence, the last 32 amino acids of WT (blue) are replaced by 19
different amino acids (purple) in IVS6-1. The phosphorylation site at Ser15 is shown in red and the RLC calcium binding loop in green. The exon-intron sequence is
modified from Weterman et al. (2013). (B) Western blots of recombinant human ventricular RLC WT and RLC IVS6-1 mutant detected with the C-terminal RLC
antibody (CT-1) and the N-terminal RLC antibody (NT-1). Note the loss of C-terminal epitope in IVS6-1 enabling the mutant to be exclusively detected with NT-1
compared with RLC-WT, detected with both, CT-1 and NT-1 antibodies.
Myosin Light Chain Kinase (MLCK)-
Dependent Phosphorylation of IVS6-1 vs.
WT RLCs
RLC WT and IVS6-1 proteins were first dialyzed into
phosphorylation buffer containing 30mM KCl, 20mM PO4, pH
8.0, and adjusted to a concentration of 1.5mg/ml. Skeletal muscle
MLCK was prepared as described previously (Greenberg et al.,
2009). Phosphorylation reaction was performed with 5.5µM
MLCK, 5µM calmodulin (CaM), 0.1mM CaCl2, 12.5mM
MgCl2, and 5mM ATP for 30min at room temperature. The
reaction was terminated by adding 8M urea. The degree of
phosphorylation was assessed by 8% PAGE. The samples were
prepared by mixing 100µl of protein with 70mg of ultrapure
urea, 10µl β-ME (β-mercaptoethanol), and 5µl of Bromophenol
Blue. 8M urea–containing gels were run at 100Volts for 180min.
Gels were scanned and analyzed using Image J software.
Preparation of Porcine Cardiac (PC) Myosin
Left ventricular (LV) muscles of pig hearts obtained postmortem
from a slaughterhouse, chilled on ice and washed clear of blood
with ice-cold H2O were isolated and minced. The muscle mince
was rinsed with ice-cold H2Ountil clear followed by extraction of
myosin using Edsall–Weber solution (0.012M Na2CO3, 0.04M
NaHCO3, and 0.6M KCl, pH 9.0; 300ml/100 g of muscle) on ice
with stirring for 1.5 h, as described earlier in Pant et al. (2009).
The homogenate was then centrifuged at 13,000 g for 20min, and
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the supernatant was precipitated with 13 vol of ice-cold water
containing 1mM EDTA (ethylenediaminetetraacetic acid) and
1mMDTT, followed by centrifugation at 13,000 g for 10min. The
pellet was resuspended in buffer containing 0.5M KCl, 20mM
MOPS (pH 7.0), 1mMDTT, and 10mMMgATP and centrifuged
at 186,000 g for 1.5 h. Supernatant containing native PC myosin
was precipitated with 14 vol of ice-cold H2O containing 1mM
DTT and centrifuged at 8000 g for 10min. The pellet (kept on
ice overnight) was resuspended in 0.5M KCl, 20mMMOPS (pH
7.0), 1mM DTT, and 10mMMgATP and centrifuged at 186,000
g for 1.5 h. The supernatant containing PC myosin was tested
for purity by SDS-PAGE, mixed with glycerol (1:1 vol/vol), and
stored at−20◦C until needed.
Depletion of Endogenous RLC from PC
Myosin and Reconstitution of Myosin with
RLC WT and IVS6-1
About 1.5mg/ml of PC myosin dissolved in 0.5M KCl
and 10mM Potassium Phosphate (pH 8.5) was incubated
in buffer containing 1% Triton X-100 and 5mM CDTA
(1,2-cyclohexylenedinitrilotetraacetic) for 30min at room
temperature to extract endogenous PC-RLC. Then the mixture
was precipitated with 13 vol of ice-cold water containing 1mM
DTT for 30min on ice and centrifuged at 8000 g for 10min. The
pellet containing RLC-depleted PC myosin was re-suspended
in reconstitution buffer (0.4M KCl, 50mM MOPS, pH 7.0,
2mM MgCl2, and 1mM DTT) to ∼2.8µM concentration
and titrated with increasing concentrations of human cardiac
WT or IVS6-1 RLCs (from 0.1 to 14µM). The molar ratio
of RLC to depleted myosin ranged from 0.1 to 5.0. Titrations
were performed in the presence of BSA to prevent nonspecific
RLC binding. The mixtures were incubated for 30min at room
temperature and then precipitated with 13 vol of ice-cold water
containing 1mM DTT for 30min on ice, and centrifuged
at 8000 g for 10min at 4◦C. The pellets containing WT or
IVS6-1 -reconstituted myosins were dissolved in small volumes
of 3M KCl to reach a final concentration of 0.5M KCl, and
clarified by ultracentrifugation at 200,000 g for 45min at 4◦C.
Resulting samples were examined by SDS-PAGE. Gel bands
were scanned and quantified using Image J software. The degree
of reconstitution was calculated based upon the RLC/ELC
band intensity ratio of native, RLC-depleted and WT/IVS6-
1-reconstituted PC myosin with ELC bands used as loading
controls (Pant et al., 2009). To account for the amount of porcine
RLC remaining in RLC-depleted myosin, the RLC/ELC ratio of
RLC-depleted myosin was subtracted from the RLC/ELC ratio of
WT-reconstituted myosin due to the similar migration pattern
of the endogenous porcine RLC and exogenous human RLC. For
IVS6-1, the band of IVS6-1 migrates independently of porcine
RLC because of different molecular weights of the two proteins,
and as such, could be assessed directly. The resultant RLC/ELC
ratio in WT/IVS6-1 reconstituted myosin was then divided by
the RLC/ELC ratio measured in native PC myosin. The binding
isotherms were fitted to the ligand binding equation:
f = y0 + Bmax ∗ x/(Kd + x) (1)
where “Bmax” depicts maximal RLC binding and Kd is apparent
dissociation constant.
Preparation of WT or IVS6-1 reconstituted myosins for the
in vitro steady state and kinetics experiments—The RLC-depleted
porcine myosin, obtained as described above, was incubated
with a 3 molar excess of human recombinant WT/IVS6-1 RLCs
and the mixtures were dialyzed for 2 h at 4◦C against the
reconstitution buffer containing 0.4M KCl, 50mM MOPS, pH
7.0, 2mM MgCl2, and 1mM DTT. The protein complexes were
centrifuged at 8000 g for 10min and then dialyzed overnight
at 4◦C against 5mM DTT to precipitate the RLC-reconstituted
myosin. The samples were then centrifuged at 8000 g for 10min
to collect the reconstituted myosins and the pellets resuspended
in 0.4M KCl, 10mMMOPS, pH 7.0, 1mMDTT. This procedure
yielded fully reconstituted IVS6-1- and WT-myosins.
Preparation of Actin and Labeling with
Pyrene Iodoacetamide
Rabbit skeletal acetone powder was extracted with a G-actin
buffer consisting of 2mM Tris-HCl (pH 8), 0.2mM Na2ATP,
0.5mM β-ME, 0.2mM CaCl2, and 0.0005% NaN3 at a ratio of
20ml g−1 for 30min with stirring on ice (Pardee and Spudich,
1982). The extract was clarified by filtration through several
layers of cheesecloth, then centrifuged at 11,000 g at 4◦C for
1 h and the tissue pellet was discarded. The supernatant was
adjusted to a final concentration of 50mM KCl, 2mM MgCl2,
and 1mM Na2ATP (pH 8.0) and the F-actin was allowed to
polymerize for 2 h at 4◦C. The KCl concentration was then
increased very slowly to a final concentration of 0.6M and the
mixture was stirred slowly on ice for 30min to remove possible
traces of tropomyosin–troponin (Tm–Tn). F-actin pellet was
then collected by ultracentrifugation at 160,000 g at 4◦C for
1.5 h. F-actin pellet was re-dissolved in a buffer containing of
10mM MOPS (pH 7.0) and 40mM KCl for pyrene labeling.
F-actin at a concentration of 20–40µM was incubated at room
temperature in the dark, for 16 h, with a 10molar excess of Pyrene
Iodoacetamide (PIA) (Invitrogen/Molecular Probes) in F-actin
buffer containing 10mM MOPS (pH 7.0) and 40mm KCl as
previously described by Cooper et al. (1983), Kazmierczak et al.
(2009). The reaction was quenched by adding 1mMDTT and the
preparation was centrifuged at 1000 g for 1 h to clarify the F-actin
solution and remove precipitated PIA. F-actin was then dialyzed
against 2mM Tris–HCl, pH 8.0, 0.2mM CaCl2, 0.2mM ATP,
and 1mM DTT overnight to depolymerize F-actin and remove
excess PIA. G-actin was then polymerized into F-actin overnight
at 4◦C by dialysis in 40mM KCl, 1mM MgCl2, and 10mM
MOPS, pH 7. Pyrene-labeled F-actin was tested spectroscopically
to determine efficiency of labeling using the molar extinction
coefficient, e344(pyrene) = 22,000 M
−1cm−1. The usual molar
ratio of pyrene/F-actin was∼0.8 (Kazmierczak et al., 2012).
Fluorescence Based Actin-Myosin Binding
Assays
RLC WT/IVS6-1 reconstituted myosin was added at
0.05µM increments to pyrene labeled F-actin (0.5µM) until
reaching ∼2 fold molar excess over the concentration of actin.
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Fluorescence measurements were carried using a JASCO 6500
Spectrofluorometer. PIA was excited at 340 nm and fluorescence
was collected at 407 nm. The titration data were fitted to the
following quadratic equation to obtain the binding constant (Kd)
and stoichiometry (n):
f = m1 −m2 (Kd + n ∗ a+ x −√
((Kd + n ∗ a+ x)2 − 4 ∗ n ∗ a ∗ x)
)
/(2 ∗ n ∗ a) (2)
Where m1 = initial signal, m2 = maximal amplitude (decrease
in fluorescence intensity on myosin binding to pyrene–actin),
n = stoichiometry of myosin-actin binding, a = concentration
of actin and x = total concentration of added myosin.
Stopped-Flow Kinetic Measurements
Reconstituted myosin at a concentration of 0.25µM were mixed
with 0.25µM pyrene labeled F-actin (stabilized by 0.25µM
phalloidin) in rigor buffer containing 0.4M KCl, 1mM DTT
and 10mM MOPS, pH 7.0. The complexes were mixed in a
1:1 (vol/vol) ratio with increasing concentrations of MgATP
(10–150µM) dissolved in the same buffer in the stopped flow
apparatus. The time course of the change in pyrene fluorescence
on MgATP-dependent myosin dissociation from actin was
monitored. Measurements were performed using a BioLogic
(Claix, France) model SFM-20 stopped-flow instrument outfitted
with a Berger ball mixer and an FC-8 observation cuvette.
The data were collected and digitized using a JASCO 6500
Fluorometer. The estimated dead time was 3.5ms. The pyrene-
F actin was excited at 347 nm and emission was monitored
at 404 nm using monochromators set to 20-nm bandwidths.
Typically, 8–12 stopped-flow records were averaged and fit to
an exponential equation to obtain the rate at a given MgATP
concentration. A plot of the observed myosin dissociation rates
as a function of [MgATP] was linear and the slope corresponded
to the rate constant expressed in M−1 ∗ s−1.
Myosin ATPase Activity Assay
Actin-activated myosin ATPase activity assays were performed
in a 120µl reaction volume in a buffer containing 25mM
imidazole, pH 7.0, 4mM MgCl2, 1mM EGTA, and 1mM DTT
and the final KCl concentration of 107mM, as described in
Kazmierczak et al. (2012). Briefly, ∼1.9µM myosin dissolved
in 0.4M KCl (in monomeric form) was added to the 96-well
microplate containing increasing concentrations of F-actin (in
µM): 0.1, 1, 2.5, 5, 7.5, 10, 15, 20, and 25. Protein mixtures
were first incubated on ice for 10min and then for another
10min at 30◦C. The reactions (run in triplicate) were initiated
with the addition of 2.5mM ATP with mixing in a Jitterbug
incubator shaker (Boekel), allowed to proceed for 20min at
30◦C and then terminated by the addition of 30µl 20%
trichloroacetic acid (TCA). Precipitated proteins were cleared by
centrifugation at 4000 g for 15min and the inorganic phosphate
was determined using the Fiske Subbarow method (Fiske and
Subbarow, 1925). Data were analyzed using the Michaelis–
Menten equation yielding the Vmax and Km parameters (Trybus,
2000).
CDTA-Extraction of Endogenous RLC from
Skinned Porcine Papillary Muscle Strips
and Reconstitution with WT and IVS6-1
Freshly isolated porcine hearts were placed in oxygenated
physiological salt solution of 140mM NaCl, 4mM KCl, 1.8mM
CaCl2, 1.0mM MgCl2, 1.8mM NaH2PO4, 5.5mM glucose,
and 50mM Hepes buffer, pH 7.4. The papillary muscles of
the left ventricles were isolated, dissected into muscle bundles
of about 20mm (length) × 3mm (diameter), and chemically
skinned in a 50% glycerol, 50% pCa 8 buffer (10−8M [Ca2+],
1mM free [Mg2+] (total MgPr -propionate = 3.88mM), 7mM
EGTA, 2.5mM [Mg-ATP2−], 20mM MOPS, pH 7.0, 15mM
creatine phosphate and 15 units/ml of phosphocreatine kinase,
ionic strength = 150mM adjusted with KPr containing 1%
Triton X-100 for 24 h at 4◦C (Muthu et al., 2014). Then the strips
were transferred to the same solution without Triton X-100 and
stored at −20◦C. Depletion of endogenous RLC from porcine
cardiac muscle preparations was achieved in strips about 1.4mm
long and 100µm wide, isolated from glycerinated papillary
muscle bundles in buffer containing 5mM CDTA, 40mM Tris,
50mM KCl, 1µg/ml pepstatin A, 0.6mM NaN3, 0.2mM PMSF,
and 1% Triton X-100, pH 8.4 and protease inhibitor cocktail
for 65min at room temparature. After depletion, the fibers were
washed in pCa 8 solution, incubated with 40µM RLC-WT or
IVS6-1 protein and 2mM DTT for total 40min with fresh
proteins added after 20min. Due to a potential partial loss of
TnC that can occur during extraction of RLC and to assure fibers’
functionality, both the RLC and TnC were added to the fiber
for another 20min of incubation. Reconstituted strips were then
washed in pCa 8 solution and subjected to force measurements.
Efficiency of depletion and RLC reconstitution was tested by
SDS-PAGE.
The Ca2+ Dependence of Force
Development
Small porcine heart ventricular muscle strips of approximately
1.4mm in length and 100µm in diameter were attached by
tweezer clips to a force transducer (Muthu et al., 2014). The strips
were placed in a 1ml cuvette and freshly skinned in 1% Triton X-
100 dissolved in pCa 8 buffer (as mentioned above) for 30min.
They were rinsed 3 times × 5min in pCa 8 buffer and their
length adjusted to remove the slack. This procedure resulted in
sarcomere length of ∼2.1µm as judged by the first order optical
diffraction pattern as described in Wang et al. (2013a), Muthu
et al. (2014). Then the strips were tested for maximal steady state
force development in pCa 4 solution (composition is the same
as pCa 8 buffer except the [Ca2+] = 10−4 M). Maximal tension
readings at pCa 4 were taken before and after the force-pCa
curve, averaged and expressed in kN/m2. The cross sectional area
of the muscle strip was assumed to be circular. After the initial
steady state force was determined, muscle strips were relaxed
in pCa 8 buffer and exposed to solutions of increasing Ca2+
concentrations from pCa 8 to pCa 4. The level of force was
measured in each “pCa” solution. Data were analyzed using the
Hill equation (Hill et al., 1980):
f = y0 +
(
a
(
10−x
)b)
/
((
10−c
)b
+
(
10−x
)b)
(3)
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where b = nH is the Hill coefficient, c = [Ca
2+]50 or pCa50, is
the free Ca2+ concentration which produces 50% of the maximal
force. The pCa50 represents the measure of Ca
2+ sensitivity of
force and the nH is the measure of myofilament cooperativity.
Secondary Structure Prediction of WT and
IVS6-1 RLCs
The secondary structure prediction was conducted with I-
TASSER (online server from Zhanglab, University of Michigan):
http://zhanglab.ccmb.med.umich.edu/I-TASSER/ as described
earlier (Huang et al., 2015; Yuan et al., 2015). The amino acid
sequence of IVS6-1-RLCwas compared against template proteins
selected from the PDB library of similar structures. The full
length protein was assembled from the excised fragments and
simulated into the lowest energy model using specific algorithms.
The confidence of each predicted model structure was presented
as C-score, ranging from −5 to 2. The quality of prediction was
proportional to the value of C-score (Zhang, 2008; Roy et al.,
2010, 2012). The predicted structures were then modeled using
PyMOLmolecular visualization system (Huang et al., 2015; Yuan
et al., 2015).
Statistical Analysis
All values are shown as means ±SD (standard deviation) for n
(number of independent experiments) ≤ 5 or ±SEM (standard
error of the mean) for n ≥ 6. Statistically significant differences
between two groups (WT and IVS6-1) were determined using an
unpaired Student’s t-test (Sigma Plot 11; Systat Software, San Jose,
CA), with significance defined as P < 0.05.
RESULTS
Molecular Effects of IVS6-1RLC Mutation
The IVS6-1 mutation originates from a frameshift within the
MYL2 gene and results in a replacement of the last 32 amino
acids by 19 different amino acids, severely altering the C-
terminus of the human cardiac RLC protein resulting in a
shorter protein sequence (153 aa for IVS6-1 vs. 166 aa for
WT) (Figure 1A). The purity of the recombinant RLC WT and
IVS6-1 proteins was tested by Western blotting with antibodies
against the C-terminus of RLC (CT-1) and its N-terminus (NT-
1) (Figure 1B), both produced in this laboratory (Szczesna-
Cordary et al., 2005; Wang et al., 2006). Due to the amino acid
changes and the C-terminal truncation of IVS6-1, the mutant
lost its C-terminal epitope and could only be detected with NT-1
(Figure 1B).
To examine the effect of C-terminal truncation mutation on
the secondary structure of the RLC, the I-TASSER computing
program was used and the RLC-like protein templates extracted
from the Protein Data Bank, as previously described (Huang
et al., 2015). Structures with high similarity to the structure
of RLC were used: PDB ID 4i2yA (chain A, crystal structure
of the genetically encoded calcium indicator Rgeco1), PDB
ID 3jvtB [chain B, calcium-bound scallop myosin regulatory
domain (lever arm) with reconstituted complete light chains],
PDB IF 3j04B (chain B, EM structure of the heavy meromyosin
subfragment of Chick smooth muscle myosin with regulatory
light chain in phosphorylated state), 1prwA (chain A, crystal
structure of bovine brain Ca2+ calmodulin in a compact form),
PDB ID 4ik1A (chain A, high-resolution structure of Gcampj
at pH 8.5), PDB ID 2mysA (chain A, myosin subfragment 1)
and PDB ID 2w4ab (chain B, isometrically contracting insect
asynchronous flight muscle). The resulting modeled structures of
RLC WT and IVS6-1 structures (Model with lowest C-score in
I-TASSER) are presented in Figures 2A,B. Figure 2C shows the
superimposed structures of WT and IVS6-1. The results show
that the majority of changes occur in the C-terminal region of
the RLC, leaving the structure of the N-terminus and the region
linking the two RLC lobes unchanged (Figure 2). In addition, I-
TASSER modeling data suggested that the RLC phosphorylation
site at Ser15 is not affected by structural rearrangements of the C-
terminus of RLC (Figure 2). We then pursued the investigation
of the ability of IVS6-1 to become phosphorylated in vitro with
the Ca2+-CaM activated MLCK (Figure 3). The slower band
migration of IVS6-1 (MW∼17220 Da) vs. WT (MW∼18789
Da) was observed, and this was because of increased pI of
the mutant (pI∼5.50) compared to WT (pI∼4.89). Likewise,
phosphorylated forms of both WT and IVS6-1 migrated faster
than their non-phosphorylated counterparts (Szczesna et al.,
2001; Figure 3). The results indicated that Ser15 of IVS6-1-
RLC could be phosphorylated by Ca2+-CaM MLCK as easily
as WT RLC. However, these in vitro solution data may
not directly translate to the in situ measures, when IVS6-
1 is incorporated into the myosin lever arm in the thick
filaments.
The Effect of IVS6-1 on RLC-MHC
Interaction
To gain insight into the effect of IVS6-1 on the assembly
of the RLC into the lever arm domain of MHC, we have
studied the binding profiles of the WT and IVS6-1 proteins to
the RLC-depleted porcine cardiac myosin. The CDTA/Triton-
based treatment yielded >80% RLC-free myosin and the level
of RLC remaining in RLC-depleted myosin was assessed by
comparing the ratio of RLC/ELC bands in RLC-depleted to
RLC/ELC of native myosin (Figure 4A). Titration experiments
of RLC-depleted PC myosin (2.8µM) incubated with increasing
concentrations of human recombinant WT or IVS6-1 (from
0.1µM to 14µM) (Figure 4B) produced the binding isotherms
(Figure 4C) and the Kd values of binding using Equation (1). We
observed a significant reduction in Kd and the maximal level of
reconstitution for IVS6-1 (Kd = 4.41 ± 0.79 (SD) µM and 57 ±
2%, n = 3) compared with WT (Kd = 1.42 ± 0.21 (SD) µM
and 77 ± 2%, n = 4) (P < 0.05). These results suggested that
the IVS6-1 truncation mutation was sufficient to impose severe
conformational changes in the RLC structure that prevented the
mutant to stoichiometrically bind to the MHC and structurally
support the lever arm of myosin. These altered protein-protein
interactions might be due to the mutant-induced changes in
the tertiary structure of the RLC (Figure 2B) that ultimately
trigger pathologic cardiac remodeling in the IVS6-1-mutated
myocardium.
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FIGURE 2 | Structure of human ventricular RLC-WT (A), RLC-IVS6-1
(B) predicted using I-TASSER, and the superimposed structures of
RLC-WT (cyan) and RLC-IVS6-1 (sand) (C). The C-terminus of RLC-WT
(light pink) is truncated and last 32 amino acids are replaced by 19 different
amino acids (purple) in IVS6-1. The phosphorylation site of RLC at Ser15 is
shown in red.
Binding of RLC-IVS6-1 Reconstituted
Myosin to Pyrene Labeled F-Actin
Fluorescence steady-state binding of IVS6-1 mutant vs. WT
reconstituted PC myosin to pyrene labeled F-actin was
investigated under rigor conditions (Figure 5). Titration profiles
of pyrene-actin with native PC myosin or WT-reconstituted
myosin were not different while those of IVS6-1-reconstituted
FIGURE 3 | Phosphorylation of IVS6-1 and WT RLCs with myosin light
chain kinase (MLCK). Representative 8% UREA (8M) PAGE of
phosphorylated vs. non-phosphorylated IVS6-1 and WT RLC proteins. 3-5
experiments were performed and the estimated level of phosphorylation was
92.7 ± 1.3% for IVS6-1 compared to 100% for WT RLC. Note the slower
migration of IVS6-1 vs. WT even though the truncation mutation decreases the
molecular weight of IVS6-1 (MW∼17220 Da) compared with WT (MW∼18789
Da). This is because the resultant pI of the IVS6-1 protein (predicted pI∼5.50)
is higher than that of WT (predicted pI∼4.89).
myosin showed impaired binding to actin. Titration data were
fitted to Equation (2) to obtain the apparent dissociation
constants (Kd) and stoichiometry n of binding (Figure 5). The
binding of PC myosin or WT/IVS6-1 reconstituted myosins to
actin was strong (in nM range), but the mutant showed a lower
binding affinity compared with WT or PC native myosin. The
data for IVS6-1 showed: Kd = 16.7± 2.8 (SD) nM; stoichiometry
n = 0.59 ± 0.0.01 (n = 3), and for WT: Kd = 4.6 ± 1.3 (SD)
nM; stoichiometry n = 0.51 ± 0.14 actin (n = 3). The binding
affinity of native myosin, used as a control, for actin was Kd =
2.9 ± 0.9 (SD) nM with stoichiometry n = 0.47 ± 0.04 (n = 4).
Therefore, IVS6-1 reduced the affinity of myosin for actin by
∼4-fold compared to WT and by ∼6-fold compared with native
PC myosin (P < 0.01). There was no statistically significant
difference in Kd between WT and native PC myosin (P = 0.103;
Figure 5).
Stopped Flow Measurements
Fluorescence stopped-flow kinetic experiments were carried out
on myosin reconstituted with RLC-WT or –IVS6-1 and pyrene
labeled F-actin to further examine the effects of IVS6-1 on
the interaction of myosin with actin. The time course of the
recovery in the pyrene fluorescence was monitored as a function
of Mg-ATP concentrations. The Mg-ATP-dependent transition
of the strongly bound acto-myosin complex (M•A) to the weakly
bound state (M•A•ATP) was measured by mixing actin-myosin
complexes in a 1:1 vol/vol ratio with increasing concentrations of
Mg-ATP (10–150µM) in a stopped flow apparatus. An increase
in the fluorescence intensity on the addition of MgATP was
monitored as a function of time (not shown) as the myosin heads
dissociated from pyrene-F-actin on the addition of MgATP. The
observed actin-myosin dissociation rate constant (k1) for theMA
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FIGURE 4 | The effect of IVS6-1 on the RLC-MHC interaction. (A) Representative 15% SDS-PAGE images of native myosin, RLC-depleted myosin and WT or
IVS6-1 reconstituted myosin. Lane 1, MW marker (kDa); lanes 2 and 9, RLC-depleted PC myosin; lanes 3 and 8, native PC myosin; lane 4, IVS6-1-RLC protein used
in reconstitution; lane 5, WT-RLC used in reconstitution; lanes 6 and 11, IVS6-1 reconstituted PC myosin; lanes 7 and 10, WT reconstituted myosin; lane 12, mixture
(Continued)
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FIGURE 4 | Continued
of WT and IVS6-1 proteins. (B) Titration experiments using RLC-depleted porcine cardiac myosin with increasing concentrations of WT or IVS6-1 RLCs. ELC (which
remained intact during the depletion/reconstitution procedure) was used as the loading control. Numbers on the top indicate the molar ratio of RLC protein used for
reconstitution to RLC-depleted PC myosin. (C) Binding isotherms of WT or IVS6-1 to RLC-depleted myosin. The data points were average of n = 4 experiments ± SD
for WT, and n = 3 for IVS6-1. The data were fitted to the ligand- binding model Equation (1). Compared to WT, the maximal level of RLC reconstitution was
significantly decreased in IVS6-1 and a significant decrease in the binding affinity to the MHC was observed for IVS6-1, *P < 0.05.
FIGURE 5 | Fluorescence steady-state binding of IVS6-1 mutant vs. WT
-reconstituted porcine myosin to pyrene labeled F-actin under rigor
conditions. 0.5µM pyrene-actin was titrated with increasing concentrations
of native (black circles), WT (open circles) or IVS6-1 (black triangles) myosins.
Note a significantly lower binding affinity of IVS6-1 reconstituted myosin to
actin compared with WT or native myosins (*P < 0.01). Three to four
experiments per group were performed.
toMAATP transition was derived from the averaged fluorescence
traces and fitted with a single exponential dependence. The values
of k1 ± SD for each MgATP concentration are presented in
Table 1. The results revealed significant differences in k1 between
IVS6-1- and WT-reconstituted myosins for 80, 125, and 150µM
Mg-ATP concentration, indicating slower dissociation rates in
IVS6-1 compared with WT. A plot of the observed transition
rates (k1) as a function of [MgATP] is presented in Figure 6,
which showed linear-type of dependence with the slope “a” value
corresponding to the effective second-order Mg-ATP binding
rates. Significantly altered binding rates were observed for IVS6-
1 compared with WT/native myosins (n = 3–5 experiments
per group) with binding rates (in M−1s−1): 4.3 ± 0.01 × 105
(IVS6-1) vs. 5.8 ± 0.02 × 105 (WT) vs. 5.5 ± 0.02 × 105
(native) (P < 0.01). No statistically significant differences
were observed between native myosin and WT-reconstituted
myosin.
Actin Activated Myosin ATPase Activity
To identify the IVS6-1-induced changes in actin-myosin
interaction, actin-activated myosin ATPase activity assays were
carried out as a function of actin concentration (in µM) using
porcine myosin reconstituted with WT or IVS6-1 RLCs. The
acto-myosin ATPase profiles of IVS6-1 mutant, WT and native
myosin control are shown in Figure 7. The data are the average
of n = 3–4 individual experiments ±SD and analyzed using
the Michaelis–Menten equation yielding the Vmax and Km
parameters (Trybus, 2000). The Vmax represents the rate constant
of the detachment step and the transition from the weakly
(A·M·ATP←→A·M·ADP·Pi) to strongly (A·M·ADP←→A·M)
bound cross-bridges (Kazmierczak et al., 2012). The IVS6-1
demonstrated significantly decreased Vmax = 0.15 ± 0.01 s
−1
(n = 3) compared with WT: Vmax = 0.25 ± 0.01 s
−1 (n = 3)
and native myosin: Vmax = 0.24 ± 0.01 (n = 4) s
−1 (Figure 7,
P < 0.05). No statistically significant differences were observed
between native PC and WT-reconstituted myosins. The results
suggested that IVS6-1 mutation may slow down the ATPase cycle
or may decrease the number of cycling cross-bridges during
muscle contraction. The Km (in µM) ±SD values were 1.93 ±
0.06, 3.67± 0.23, and 3.33± 0.57 for native PC, WT-, and IVS6-
1 reconstituted myosins. No statistical significance was noted
between WT and IVS6-1 (P > 0.05).
Steady-State Force and Force-pCa
Relationship in WT- and IVS6-1-
Reconstituted Porcine Papillary Muscle
Strip
To further assess the effects of IVS6-1 on cardiac muscle
contraction, the RLC WT or IVS6-1 -reconstituted skinned
porcine papillary muscle strips were subjected to force-pCa
measurements. A significant decrease in maximal isometric force
was observed in fibers reconstituted with IVS6-1 compared with
WT (Figure 8A). The values of force per cross-sectional area of
muscle (in kN/m2 ± SEM) were: IVS6-1, 27 ± 1.0 (n = 6) vs.
WT, 35 ± 2.0 (n = 8). The average diameter of muscle strips
(inµm) was 89 ± 5 for IVS6-1 and 101 ± 5 for WT. The data
of force-pCa measurements were plotted and fitted using the
Hill equation (Equation 3). There was a statistically significant
increase in pCa50 of the force-pCa dependence: pCa50 = 5.66
± 0.01 observed for IVS6-1 compared with 5.48 ± 0.01 for WT
(Figure 8B, P < 0.05). The IVS6-1 mutation also affected the
Hill coefficient, and 2.90 ± 0.15 was observed for IVS6-1 and
2.20± 0.14 for WT (Figure 8B). The efficiency of RLC-depletion
and reconstitution with RLC/IVS6-1 proteins was tested by SDS-
PAGE and is shown in Figure 8C. On average, more than 80% of
RLC-depletion, and near 100% fiber reconstitution was observed
for both WT and IVS6-1 proteins. The results from functional
studies indicated that IVS6-1 was able to bind to the lever arm
domain ofmyosin cross-bridge and impose significant alterations
in the force-pCa dependence and in the ability of myosin to
develop maximal isometric force.
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TABLE 1 | Stopped-flow kinetics of MgATP induced actin-myosin dissociation.
Samples MgATP concentration
10µm 25µm 40µm 60µm 80µm 125µm 150µm
Native 6.2 ± 0.9 15.8 ± 3.6 24.5 ± 2.6 33.4 ± 3.3 47.2 ± 1.9 65.9 ± 5.7 86.8 ± 2.6
WT 7.4 ± 1.3 15.6 ± 1.3 19.9 ± 0.9 36.0 ± 4.6 50.4 ± 3.7 70.4 ± 5.8 88.7 ± 7.1
IVS6-1 5.5 ± 1.8 14.4 ± 0.7 21.0 ± 4.4 30.5 ± 2.2 41.4 ± 1.9a 57.5 ± 2.3a 67.8 ± 6.8a
Pyrene-labeled F-actin was complexed with IVS6-1 or WT –reconstituted myosin. The dissociation rates k1 were in s
−1, n = 5–10.
aP < 0.05 compared with WT.
FIGURE 6 | The dissociation rate (k1)–[MgATP] dependence and the
effective second-order MgATP binding rates (a = slope) for native
porcine myosin and RLC-depleted porcine myosin reconstituted with
WT, IVS6-1 complexed with F-actin. The values of k1 ± SD for each
MgATP concentration are presented in Table 1. Significantly altered binding
rates were observed for IVS6-1 compared with WT (*P < 0.05). No statistically
significant differences were observed between native myosin and
WT-reconstituted myosin.
DISCUSSION
Myosin regulatory and essential light chains bind to the myosin
heavy chain at the lever arm domain (Rayment et al., 1993b;
Geeves, 2002) and structurally support this region of the myosin
head contributing to its stiffness and cross-bridge compliance
(Muthu et al., 2011; Wang et al., 2013a,b). They also actively
participate in the ATP-powered myosin cross-bridge cycle and
muscle contraction (Rayment et al., 1993a; Geeves and Holmes,
2005). The cardiac myosin RLC belongs to the superfamily of the
EF-hand Ca2+-binding proteins and its N-terminal tail contains
one Ca2+-Mg2+ binding site (Lowey and Risby, 1971; Alexis and
Gratzer, 1978). It has been postulated that during cardiac muscle
contraction, this RLC site may work as a delayed Ca2+ buffer
helping SERCA2a pump Ca2+ back to the SR (sarcoplasmic
reticulum) during diastole (Wang et al., 2006; Szczesna-Cordary
et al., 2007). The N-terminus of cardiac RLC also contains
the Ca2+/CaM-MLCK dependent phosphorylation site at Ser15,
which can become phosphorylated when Ca2+ is released from
the SR and activates the myosin light chain kinase (Kamm and
FIGURE 7 | The effect of splice site RLC mutation on the
actin-activated myosin ATPase activity. Note that IVS6-1 (black triangles)
resulted in significantly lower Vmax compared with native porcine myosin
(black circles) and WT reconstituted myosin (open circles). Porcine cardiac
myosin followed the same procedures that were used for experimental
myosins and served as a control. The data are the average of n = 3–4
experiments for each group of myosins ±SD. The “*” symbol denotes
significant changes with P < 0.05.
Stull, 2001). Our previous research showed that the properties
of both of these two functional sites (Ca2+-binding site and
phosphorylation site) of the RLC can be significantly altered in
the presence of cardiomyopathy-associated mutations in MYL2
(Szczesna et al., 2001; Szczesna-Cordary et al., 2004).
In this report we describe a novel MYL2 mutation, which
was recently identified to be responsible for a long known
cardioskeletal myopathy observed in Dutch and Italian families
(Barth et al., 1998; Weterman et al., 2013) The genetic cause
for this hereditary disorder resulting in skeletal and cardiac
muscle myopathy was found to be due to mutations in the gene
encoding for the ventricular and slow twitch skeletal isoforms
of the RLC, MYL2 (Weterman et al., 2013). The most severe of
all was the splice site mutation located in the intron 6 of MYL2
(IVS6-1) that ultimately resulted in the C-terminal truncation
of the RLC protein changing its amino acid sequence at the
C-terminal tail of RLC (Weterman et al., 2013). The homozygous
appearance of IVS6-1 led to the early death of infants (4–6
months of age) due to dilated (DCM), hypertrophic (HCM) or
non-compaction cardiomyopathy, while no obvious phenotype
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FIGURE 8 | (A) Maximal force measured in pCa 4 after RLC and TnC
reconstitution in porcine papillary muscle fibers. Note that IVS6-1 imposed a
significant reduction in maximal level of tension in IVS6-1 reconstituted fibers
(n = 6) compared with WT reconstituted fibers (n = 8) (*P < 0.05). The average
diameter of muscle strips (inµm) was 89 ± 5 for IVS6-1 and 101 ± 5 for WT.
(B) IVS6-1- induced increase in Ca2+ sensitivity of force. The number of
experiments as in A. There was a significant difference between pCa50 of
(Continued)
FIGURE 8 | Continued
IVS6-1 vs. WT reconstituted fibers (*P < 0.05). (C) Representative 15%
SDS-PAGE of CDTA depleted and RLC/TnC reconstituted porcine papillary
muscle strips. Lane 1, native PC fiber; lane 2, recombinant human cardiac
WT-RLC protein used for fiber reconstitution; lane 3, recombinant human
cardiac IVS6-1-RLC protein used for fiber reconstitution; lanes 4, 5, 7, and 8,
IVS6-1 reconstituted fibers; lane 6, RLC-depleted fiber; lanes 9 and 10,
WT-reconstituted fibers.
was noted in family members heterozygous for IVS6-1 (Barth
et al., 1998; Weterman et al., 2013). The homozygous patients
demonstrated dual cardiac and skeletal muscle myopathy with
morphological features of muscle type I hypotrophy and the
skeletal and cardiac myofibril disorganization.
Here, we have examined the molecular and functional
consequences of IVS6-1 in vitro using recombinant IVS6-1 and
wild-type RLC proteins that could be reconstituted into RLC-
depleted porcine cardiac muscle preparations (PC myosin, acto-
myosin complex and skinned papillary muscle strips). As the
IVS6-1 mutation arose from a frameshift in the MYL2 gene,
the resultant protein demonstrated a replacement of the last
32 amino acids by 19 different amino acids. The molecular
analysis of the mutation-induced conformational changes in the
RLC molecule using I-TASSER computation (Huang et al., 2015;
Yuan et al., 2015) clearly showed the C-terminal RLC molecular
rearrangements due to IVS6-1. The observed differences between
WT RLC and the mutant with the latter being 13-amino acid
shorter were observed in the newly formed C-terminus of IVS6-1.
Interestingly, IVS6-1 did not eliminate the ability for MLCK-
induced phosphorylation of the RLC in vitro, which was not
surprising given that the accessibility of Ser15 was not observed
to be obstructed by the C-terminal RLC truncation in IVS6-
1. In vivo, the RLC phosphorylation was shown to be a
significant modulatory mechanism of myosin activation and
muscle contraction, and a severely decreased level of RLC
phosphorylation was observed in the hearts of HCM and/or heart
failure patients (Van Der Velden et al., 2003a,b,c) and in the
animal models of HCM (Abraham et al., 2009; Muthu et al., 2010,
2012; Yuan et al., 2015). Future studies will have to be executed
to examine the effect of IVS6-1 on myosin RLC phosphorylation
in vivo.
Since the C-terminal region of the RLC is involved in
its interaction with the myosin heavy chain (Rayment et al.,
1993b), we proceeded to examine the effect of IVS6-1 truncation
mutation on the incorporation of the mutant RLC into the
myosin lever arm domain. The data revealed that the mutation
was sufficient to disrupt the RLC-MHC interaction and reduce
the Kd of binding. This altered RLC-MHC interaction in the
mutant was most likely responsible for the significant changes
that we observed in the interaction of the mutant-reconstituted
myosin and actin. While no differences in the binding profile to
pyrene-labeled F-actin between the native or WT-reconstituted
PC myosin were observed, the affinity of IVS6-1 -reconstituted
myosin for pyrene-actin was ∼4-fold lower compared with WT.
Therefore, the truncation mutation of the RLC and the changes
in the amino acid sequence of its new C-terminus resulted in
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a significantly reduced affinity of IVS6-1-mutant myosin to F-
actin. Likewise, the stopped-flow kinetics of the myosin–actin
interaction were significantly reduced with decreased slope of
the kobs-[MgATP] relationship for IVS6-1-reconstituted myosin
compared with WT. These results suggest that IVS6-1 mutation
may not only lower the affinity of the myosin-actin binding,
but also reduces the kinetics of the ATP-induced dissociation of
IVS6-1 myosin from actin. Results from actin-activated myosin
ATPase activity assays and significantly decreased Vmax (by 1.7-
fold compared with WT) are in agreement with stopped-flow
data. These in vitro results may explain what has been observed
in skinned muscle fiber strips where the calcium sensitivity of
tension was significantly increased and the maximal level of
tension was significantly reduced in IVS6-1-recnstituted fibers
compared with WT. Interestingly, the effects on contractile force
and myofilament calcium sensitivity observed in this study were
similar to previously reported effects of other HCM-associated
mutations in myosin RLC, investigated in transgenic RLC mice
(Abraham et al., 2009; Kerrick et al., 2009; Yuan et al., 2015).
Our collective results suggest that the IVS6-1 mutation may
lead to cardiac dysfunction by disrupting the RLC-MHC and
acto-myosin interactions (steady-state and kinetics) ultimately
leading to compromised ability of the mutant myosin to develop
contractile force and sensitizing myofilaments to calcium, effects
that are hallmarks of HCM disease.
LIMITATIONS, CONCLUDING REMARKS
AND FUTURE DIRECTIONS
An important issue which was not addressed experimentally
here is the effect of IVS6-1 mutation in heterozygous state
with 50:50 ratio of WT and IVS6-1 proteins. Heterozygous
patients for IVS6-1± have no cardiomyopathy or slow-twitch
skeletal myopathy symptoms; however, no data on protein
expression were presented in the heterozygous parents of IVS6-
1+/+ toddlers (Weterman et al., 2013). Higher than 80% IVS6-1
reconstitution, achieved in porcine cardiac muscle preparations,
most likely resembles the homozygous state. Our results suggest
that when placed in vivo IVS6-1+/+ may lead to diastolic and
systolic dysfunction by delaying muscle relaxation, increasing
calcium sensitivity of contraction and reducing maximal force
generation. These speculations are supported by measurements
of the acto-myosin kinetics and the observation of slower
myosin cross-bridge turnover rates and slower second-order
MgATP binding rates in IVS6-1 vs. WT reconstituted PC cardiac
myosin. Our previous studies of the D166V RLC mutation,
located at the last amino acid residue of the human cardiac
RLC had shown similar effects on force generation in skinned
papillary muscle fibers from the hearts of transgenic mice,
i.e., significantly increased the Ca2+-sensitivity of contraction,
diminished maximal tension and delayed muscle relaxation
(Kerrick et al., 2009). These observations in skinned papillary
muscle fibers from D166V mice were further confirmed by
echocardiography and invasive hemodynamics showing systolic
and diastolic dysfunction inD166mice (Yuan et al., 2015). Future
studies on IVS6-1 animal models are necessary to associate this
truncationmutation in the RLCwith cardiac dysfunction causing
the early death of IVS6-1+/+ infants.
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